Nephros (NEPH) Projected to Announce Quarterly Earnings on Thursday

Nephros (NASDAQ:NEPH) is expected to announce its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Nephros to post earnings of $0.01 per share and revenue of $4.9940 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:30 PM ET.

Nephros (NASDAQ:NEPH) last released its earnings results on Thursday, May 7th. The company reported $0.01 earnings per share for the quarter, meeting the consensus estimate of $0.01. Nephros had a return on equity of 7.66% and a net margin of 4.06%.The firm had revenue of $5.21 million for the quarter, compared to analyst estimates of $5.02 million. On average, analysts expect Nephros to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Nephros Stock Performance

NASDAQ:NEPH traded up $0.04 on Tuesday, reaching $3.54. The company’s stock had a trading volume of 271 shares, compared to its average volume of 31,926. Nephros has a 1-year low of $2.66 and a 1-year high of $6.42. The firm has a market cap of $38.50 million, a PE ratio of 49.94 and a beta of 1.51. The business’s 50-day moving average price is $3.47 and its two-hundred day moving average price is $3.54.

Institutional Trading of Nephros

A number of institutional investors have recently modified their holdings of NEPH. Kestra Advisory Services LLC bought a new position in shares of Nephros during the fourth quarter worth about $29,000. Dimensional Fund Advisors LP bought a new stake in Nephros in the 3rd quarter valued at approximately $64,000. Heron Bay Capital Management bought a new stake in Nephros in the 4th quarter valued at approximately $66,000. Citadel Advisors LLC grew its stake in shares of Nephros by 39.2% during the 3rd quarter. Citadel Advisors LLC now owns 16,545 shares of the company’s stock worth $78,000 after acquiring an additional 4,655 shares in the last quarter. Finally, XTX Topco Ltd grew its stake in shares of Nephros by 48.5% during the 4th quarter. XTX Topco Ltd now owns 21,617 shares of the company’s stock worth $105,000 after acquiring an additional 7,062 shares in the last quarter. 41.10% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently weighed in on NEPH shares. Zacks Research upgraded Nephros to a “hold” rating in a report on Monday, July 20th. Weiss Ratings cut Nephros from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, July 17th. Finally, Northland Securities assumed coverage on shares of Nephros in a report on Friday, July 17th. They set a “market perform” rating and a $4.00 target price on the stock. One equities research analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, Nephros has a consensus rating of “Hold” and a consensus price target of $5.00.

About Nephros

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.